A minimal PSMA receptor density threshold is required to get any treatment response while factors that determine treatment response to [177Lu]PSMA therapy are homogeneity of PSMA receptor expression across cancer cells, radiation sensitivity, and a hypoxic status of these cells [78]. This evidence concerns the gene FOLH1 and cancer.